「Polio」の版間の差分
ナビゲーションに移動
検索に移動
Vaccipedia.admin (トーク | 投稿記録) |
Vaccipedia.admin (トーク | 投稿記録) |
||
(同じ利用者による、間の4版が非表示) | |||
1行目: | 1行目: | ||
+ | {{TM menu}} | ||
+ | |||
==poliovirus== | ==poliovirus== | ||
*family ''Picornaviridae'', genus ''Enterovirus'' | *family ''Picornaviridae'', genus ''Enterovirus'' | ||
17行目: | 19行目: | ||
**in recent 12 months no local transmission in Southeast Asia | **in recent 12 months no local transmission in Southeast Asia | ||
*cVDPV3 is not identified so far | *cVDPV3 is not identified so far | ||
+ | |||
+ | *VDPV is relatively physically stable in environment but cannot keep infectivity not for long time, thus continuous detection of VDPV in enviromnent means continuous transmission and/or excretion of VDPV from people living in the community | ||
+ | *distribution of breech (disinfectant) and/or irradication ultraviolet light may be effective against PV/VDPV | ||
+ | *threshold of immunization coverage to maintain PV/VDPV free is 85-90% | ||
==Global Polio Eradication | ==Global Polio Eradication | ||
26行目: | 32行目: | ||
*AFP cases and true poliovirus infection overlap very little | *AFP cases and true poliovirus infection overlap very little | ||
**⇔Variola cases and true smallpox infection overlapped almost identically | **⇔Variola cases and true smallpox infection overlapped almost identically | ||
+ | |||
+ | |||
+ | *novel OPV2 | ||
+ | **using genetically modified stain | ||
+ | **more stabilized genomically | ||
==clinical== | ==clinical== |
2021年5月30日 (日) 16:48時点における最新版
Navigation Menu |
General issues of Vaccine | |||||||
---|---|---|---|---|---|---|---|
|
General issues of Travel med. | ||||||||
---|---|---|---|---|---|---|---|---|
|
Immunology | |||||||
---|---|---|---|---|---|---|---|
|
Epi & Stats | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Virus | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
COVID-19 | |||||
---|---|---|---|---|---|
|
Bacteria | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Rickettsia | |||||
---|---|---|---|---|---|
|
Protozoa | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Fungi | |||||||
---|---|---|---|---|---|---|---|
|
Nematode (roundworm) | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Trematode (fluke, distoma) | |||||||
---|---|---|---|---|---|---|---|
|
Cestode (tapeworm) | ||||||
---|---|---|---|---|---|---|
|
Medical Zoology | ||||||||
---|---|---|---|---|---|---|---|---|
|
poliovirus
- family Picornaviridae, genus Enterovirus
- Human enterovirus A, B, C, D
- PV belongs to HEV-C
- EV71 belongs to HEV-A
- EV68 (EV-D68) belongs to HEV-D
- Human enterovirus A, B, C, D
- non-enveloped single stranded positive sense RNA virus
- 4 capsid proteins
- 3 serotypes
- wPV2 already eradicated in 2015
- wPV3 was declared to be eradicated in 17 October 2019 by WHO
- wPV1 is still circulating in Pakistan and Afghanistan
- African region was certified as wild polio-free in 2020 by WHO
VDPV
- cVDPV1 and cVDPV2 are endemic in Africa and Southeast Asia as well as in Pakistan and Afghanistan
- in recent 12 months no local transmission in Southeast Asia
- cVDPV3 is not identified so far
- VDPV is relatively physically stable in environment but cannot keep infectivity not for long time, thus continuous detection of VDPV in enviromnent means continuous transmission and/or excretion of VDPV from people living in the community
- distribution of breech (disinfectant) and/or irradication ultraviolet light may be effective against PV/VDPV
- threshold of immunization coverage to maintain PV/VDPV free is 85-90%
==Global Polio Eradication
- strategies
- extensive immunization with OPV or IPV
- surveillance of acute flaccid paralysis
- lab diagnosis
- AFP cases and true poliovirus infection overlap very little
- ⇔Variola cases and true smallpox infection overlapped almost identically
- novel OPV2
- using genetically modified stain
- more stabilized genomically
clinical
- mostly asymptomatic
- many mild manifestation
- polio paralytic cases 79% by wPV1, 8% by wPV2, 13% by wPV3 in 2010